Prevention of Early Menopause Study (POEMS): is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa)?

Archives of Gynecology and Obstetrics

Volumn 290, Issue 6, 2014, Pages 1051-1053

  Gerber, B ^a   Ortmann, O ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Breast cancer; Chemotherapy; GnRHa; Ovarian failure

Indexed keywords

GONADORELIN ASSOCIATED PEPTIDE DERIVATIVE; TAMOXIFEN; ANTINEOPLASTIC AGENT; GONADORELIN;

AMENORRHEA; ARTICLE; BIRTH RATE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY MENOPAUSE; HUMAN; MENSTRUATION; OVARY FUNCTION; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; TREATMENT DURATION; ADULT; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; MIDDLE AGED; OVARY; OVULATION; PHYSIOLOGY; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MENOPAUSE, PREMATURE; MENSTRUATION; MIDDLE AGED; OVARY; OVULATION; PREGNANCY; PREGNANCY RATE; PRIMARY OVARIAN INSUFFICIENCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84920972730     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3493-0     Document Type: Article

References (12)

1. Moore HCF, Unger JM et al (2014) Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: an international intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol 32:5s (suppl; abstr LBA505)
2. Gerber B, Dieterich M, Muller H et al (2008) Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res Treat 108:1–7
3. Swain SM, Land SR, Ritter MW et al (2008) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113:315–320
4. Ganz PA, Land SR, Geyer CE Jr et al (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29:1110–1116
5. Park IH, Han HS, Lee H et al (2012) Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer. Ann Oncol 23:2283–2289
6. Partridge AH (2012) Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy? J Clin Oncol 30:479–481
7. Badawy A, Elnashar A, El Ashry M et al (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697
8. Sverrisdottir A, Nystedt M, Johansson H et al (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567
9. Del Mastro L, Boni L, Michelotti A et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306:269–276
10. Gerber B, von Minckwitz G, Stehle H et al (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334–2341
11. Munster PN, Moore AP, Ismail-Khan R et al (2012) Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533–538
12. Elgindy EA, El Haieg DO, Khorshid OM et al (2013) Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 121:78–86